Abstract
Background: Raloxifene is a selective estrogen receptor (ER) modulator (SERM) used for the treatment of osteoporosis. However, its efficacy and also its safety vary greatly among treated patients, and it might be influenced by the individuals’ genetic background. As the receptor activator of the nuclear factor κB (RANK) ligand (RANKL)/RANK/osteoprotegerin (OPG) system is essential for osteoclastogensis and Wnt signaling pathway for osteoblastogenesis, we decided to evaluate the raloxifene treatment in regard to selected polymorphisms in key genes of these two main bone regulatory pathways.
Methods: Fifty-six osteoporotic postmenopausal women treated with raloxifene were genotyped for 11 polymorphisms located in six genes: -290C>T, -643C>T, and -693G>C in tumor necrosis factor receptor superfamily member 11 (TNFSF11), +34694C>T, +34901G>A, and +35966insdelC in tumor necrosis factor receptor superfamily member 11A (TNFRSF11A), K3N and 245T>G in tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), A1330V in LRP5, I1062V in LRP6, and -1397_-1396insGGA in SOST. For evaluation of treatment efficacy, bone mineral density (BMD) and biochemical markers of bone turnover were measured.
Results: One-year change in total hip BMD was associated with +34901G>A in TNFRSF11A (p=0.040), whereas, for lumbar spine BMD, the association was shown for -1397_-1396insGGA in SOST (p=0.015). C-terminal crosslinking telopeptides of type I collagen (CTX) concentrations showed significant association with -643C>T single nucleotide polymorphism (SNP) in TNFSF11 (p=0.049) and +34694C>T in TNFRSF11A (p=0.022). No other association was found between 1-year change in BMDs or biochemical markers and the studied SNPs.
Conclusions: We have shown that, in postmenopausal osteoporotic women treated with raloxifene, the efficacy of raloxifene treatment might be influenced by +34901G>A in TNFRSF11A gene and -1397_-1396insGGA in the SOST gene as well as -643C>T in TNFSF11 gene and +34694C>T in TNFRSF11A gene. However, these findings need additional functional and clinical confirmation for potential pharmacogenetic use in the future.
Acknowledgments
This work was supported by grants P3-0298 and J3-2330 provided by the Slovenian Research Agency.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research support played no role in thestudy design; in the collection, analysis, and interpretationof data; in the writing of the report; or in the decision tosubmit the report for publication.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002;359:2018–26.10.1016/S0140-6736(02)08827-XSearch in Google Scholar
2. Recker RR, Mitlak BH, Ni X, Krege JH. Long-term raloxifene for postmenopausal osteoporosis. Curr Med Res Opin 2011;27: 1755–61.10.1185/03007995.2011.606312Search in Google Scholar PubMed
3. Palomba S, Orio Jr F, Russo T, Falbo A, Tolino A, Manguso F, et al. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int 2005;16:943–52.10.1007/s00198-004-1800-5Search in Google Scholar PubMed
4. Palombo S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, et al. Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum Reprod 2003;18:192–8.10.1093/humrep/deg031Search in Google Scholar PubMed
5. Mencej-Bedrač S, Preželj J, Kocjan T, Teskač K, Ostanek B, Šmelcer M, et al. The combinations of polymorphisms in vitamin D receptor, osteoprotegerin and tumour necrosis factor superfamily member 11 genes are associated with bone mineral density. J Mol Endocrinol 2009;42:239–47.10.1677/JME-08-0108Search in Google Scholar PubMed
6. Zupan J, Mencej-Bedrač S, Jurković-Mlakar S, Preželj J, Marc J. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women. J Steroid Biochem Mol Biol 2010;118:102–6.10.1016/j.jsbmb.2009.10.013Search in Google Scholar PubMed
7. Arko B, Preželj J, Kocijančič A, Komel R, Marc J. Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. Maturitas 2005;51:270–9.10.1016/j.maturitas.2004.08.006Search in Google Scholar PubMed
8. Mencej-Bedrač S, Preželj J, Kocjan T, Komadina R, Marc J. Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population. Calcif Tissue Int 2009;85:501–6.10.1007/s00223-009-9306-ySearch in Google Scholar PubMed
9. Bashir A, Mak YT, Sankaralingam S, Cheung J, Mc Gowan NW, Grigoriadis AE, et al. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene. Steroids 2005;70:847–55.10.1016/j.steroids.2005.04.011Search in Google Scholar PubMed
10. Chen H, Gilbert LC, Lu X, Liu Z, You S, Weitzmann MN, et al. A new regulator of osteoclastogenesis: estrogen response element-binding protein in bone. J Bone Miner Res 2011;26:2537–47.10.1002/jbmr.456Search in Google Scholar PubMed PubMed Central
11. Mirza FS, Desmond Padhi I, Raisz LG, Lorenzo JA. Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women. J Clin Endocrinol Metab 2010;95:1991–7.10.1210/jc.2009-2283Search in Google Scholar PubMed PubMed Central
©2014 by Walter de Gruyter Berlin/Boston
